A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This single arm study evaluated the efficacy and safety of a combination of Tarceva and
Avastin in patients with advanced or metastatic liver cancer. Patients were treated with
Tarceva 150 mg po daily plus Avastin 5 mg/kg intravenous (iv) every 2 weeks. The anticipated
time on study treatment was until disease progression, and the target sample size was <100
individuals.